HIVE
HIVE Digital Technologies Ltd.
There isn't enough reported data to score HIVE yet.
HOOD
Robinhood Markets, Inc.
HOOD's fundamentals are mixed, but it looks cheap: trading at 38x earnings, below its usual 51x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIVE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
HIVE's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIVE.
HOOD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
HOOD's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like HOOD.
HIVE PE Valuation
HIVE has no meaningful PE right now: it lost money over the past year.
HOOD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 30x | $81.35 | — |
| Cheap | 37x | $78.84 | -3.1% |
| Current | 38x | $81.35 | — |
| Fair | 51x | $110 | +35% |
| Expensive | 74x | $160 | +96% |
Historical ranges are pointers, not guarantees.
HOOD's PE is in its cheap range at 38x. If earnings grow as analysts expect, today's price would be 30x next year's earnings.
HIVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect HIVE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HOOD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect strong earnings and revenue growth for HOOD, with profitability improving. However, they disagree widely on these estimates.
HIVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.60 | -1433% |
| Q2 2026 | -$1.38 | -1162% |
| Q1 2026 | -$0.66 | -$0.44 |
| Q4 2025 | -$0.27 | -154% |
| Q3 2025 | $0.12 | -71% |
| Q2 2025 | $0.13 | -28% |
| Q1 2025 | -$0.22 | -238% |
| Q4 2024 | $0.50 | +$0.98 |
HIVE has swung to a loss: it lost $1.60 per share over the past year, after a profit the year before.
HOOD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.72 | +26% |
| Q3 2026 | $2.16 | -10% |
| Q2 2026 | $2.26 | +15% |
| Q1 2026 | $2.06 | +18% |
| Q4 2025 | $2.05 | +31% |
| Q3 2025 | $2.40 | +314% |
| Q2 2025 | $1.96 | +513% |
| Q1 2025 | $1.75 | +1150% |
| Q4 2024 | $1.56 | +$2.17 |
HOOD has the edge over HIVE on earnings quality, reporting a profit while its opponent remains loss making.
HIVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.9M | -2.7% |
| Q2 2026 | $79.1M | +73% |
| Q1 2026 | $71.8M | +130% |
| Q4 2025 | $93.1M | +219% |
| Q3 2025 | $87.3M | +285% |
| Q2 2025 | $45.6M | +41% |
| Q1 2025 | $31.2M | -16% |
| Q4 2024 | $29.2M | -6.5% |
HIVE's revenue is growing: $85M last quarter, down 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -227% | -232 points |
| Q4 2025 | 18% | +25 points |
| Q3 2025 | -11% | +9.1 points |
| Q2 2025 | 78% | +132 points |
| Q1 2025 | 5.2% | -84 points |
| Q4 2024 | -7% | -30 points |
| Q3 2024 | -20% | -6.7 points |
| Q2 2024 | -54% | -68 points |
HIVE's operating margin was −227% last quarter, down 232 points from the same quarter a year ago, near the bottom of its range since 2019.
HOOD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +12% |
| Q2 2026 | $1.3B | +32% |
| Q1 2026 | $1.1B | +15% |
| Q4 2025 | $1.3B | +27% |
| Q3 2025 | $1.3B | +100% |
| Q2 2025 | $989M | +45% |
| Q1 2025 | $927M | +50% |
| Q4 2024 | $1B | +115% |
HOOD's revenue has grown year over year for 16 quarters in a row: $1.4B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | -5.9 points |
| Q2 2026 | 54% | +9.5 points |
| Q1 2026 | 39% | -1.5 points |
| Q4 2025 | 52% | -3.5 points |
| Q3 2025 | 50% | +26 points |
| Q2 2025 | 45% | +17 points |
| Q1 2025 | 40% | +14 points |
| Q4 2024 | 55% | +49 points |
HOOD's operating margin was 44% last quarter, down 5.9 points from the same quarter a year ago.
HIVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $858K | +$49.1M |
| Q2 2026 | -$10.7M | +$26.4M |
| Q1 2026 | -$21.8M | +$7.8M |
| Q4 2025 | -$9M | +$80.9M |
| Q3 2025 | -$48.2M | -$26.2M |
| Q2 2025 | -$37.1M | -$19.4M |
| Q1 2025 | -$29.5M | +$8.3M |
| Q4 2024 | -$89.9M | -$63.8M |
HIVE's free cash flow was −$41M over the past year, against −$205M the year before. Free cash flow isn't a meaningful measure for financial services companies like HIVE.
HOOD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +$2.8B |
| Q2 2026 | $720M | -79% |
| Q1 2026 | $2B | +217% |
| Q4 2025 | -$937M | +$463M |
| Q3 2025 | -$1.6B | -187% |
| Q2 2025 | $3.5B | +6398% |
| Q1 2025 | $642M | +$1.3B |
| Q4 2024 | -$1.4B | -246% |
HOOD has the edge over HIVE on cash generation, producing positive trailing cash flow while its opponent burns cash.
HIVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +7.8M shares |
| 1 year | +20% | +45.9M shares |
| 3 years | +222% | +189M shares |
| 5 years | +242% | +194M shares |
| Available history | +319% | +209M shares |
HIVE has 274M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
HOOD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -1M shares |
| 1 year | -0.8% | -6.9M shares |
| 3 years | +1.8% | +15.9M shares |
| 5 years | +292% | +679M shares |
| Available history | +7.2% | +60.8M shares |
HOOD has the edge over HIVE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25M |
| Q2 2026 | $414M |
| Q1 2026 | $250M |
| Q4 2025 | $100M |
| Q3 2025 | $107M |
| Q2 2025 | $124M |
| Q1 2025 | $322M |
| Q4 2024 | $160M |
HOOD spent $789M buying back its own shares over the past year, up 11% from the year before.
HIVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.0x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.3x | Very low |
| Q2 2024 | 0.0x | Very low |
HIVE's net debt is about 1.8 years of its operating earnings (EBITDA), down from 4.1 years a year ago. Net leverage isn't a meaningful measure for financial services companies like HIVE.
HOOD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.1x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
HOOD has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HOOD.
HIVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 6.1 | Oversold |
HIVE's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
HOOD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 9.5 | Oversold |
HOOD's weekly RSI is 41 (neutral) and its Stochastic is 10 (oversold).
HIVE PE vs Financial Services Sector
| Metric | HIVE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
HIVE has no meaningful PE right now: it lost money over the past year.
HOOD PE vs Financial Services Sector
| Metric | HOOD | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 13x | 189% above |
| PE % | 22 | 66 | 44 pts below |
HOOD is trading at 38x earnings, a 189% premium to the Financial Services sector's median of 13x.
HIVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 26% below |
| 20 week MA | $2.70 | 39% below |
| 50 week MA | $2.79 | 41% below |
| 100 week MA | $2.78 | 41% below |
| 200 week MA | $3.12 | 47% below |
HIVE is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
HOOD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.8 | 17% below |
| 20 week MA | $102.2 | 20% below |
| 50 week MA | $95.4 | 15% below |
| 100 week MA | $88.5 | 8.1% below |
| 200 week MA | $52.1 | 56% above |
HOOD has the edge over HIVE on trend strength, trading above more of its moving averages.
HIVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $8.30 | +1975% |
| 2021 | $8.30 | $15.3 | +84% |
| 2022 | $15.3 | $1.59 | -90% |
| 2023 | $1.59 | $4.53 | +185% |
| 2024 | $4.53 | $2.97 | -34% |
| 2025 | $2.97 | $2.72 | -8.4% |
| 2026 YTD | $2.72 | $1.65 | -39% |
HIVE's yearly returns have swung widely, from +1975% in 2020 to −90% in 2022. It's down 39% so far in 2026.
HOOD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $35.2 | $18.9 | -46% |
| 2022 | $18.9 | $7.95 | -58% |
| 2023 | $7.95 | $12.7 | +60% |
| 2024 | $12.7 | $39.0 | +206% |
| 2025 | $39.0 | $118.1 | +203% |
| 2026 YTD | $118.1 | $81.4 | -31% |
HOOD has the edge over HIVE on returns for 2026, with the stronger performance.